Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

How Much Should We Exercises to Reduce Mortality?

Physical activity has been shown to reduce mortality in a dose/response manner, just like any drug. But many still wonder: are there any minimal requirements in terms of amount or intensity? Is there such a thing as “toxic exercise”? And finally, is exercising equally beneficial to all?

Programas de ejercicios en la enfermedad vascular periférica

This study, conducted by Dr Sang-Woo Jeong from the Cardiovascular Department of Seoul National University, published in the European Heart Journal, answers all these concerns. 

The current guidelines recommend between 500 and 1000 metabolic units (METs) minutes per week of regular physical activity. This is the same as telling our patients they can drink 20 gr of absolute alcohol per day. Patients stare back at us clueless, wondering the same we do. They want to know how many pints of beer, glasses of wine or whiskeys they can drink safely. It happens the same with exercise.


Read also: Supervised Exercise and Revascularization for Intermittent Claudication.


Light physical activity (such as leisurely walking or strolling) equals 2.9 METS; moderate physical activity (brisk walking, cycling or playing tennis doubles) equals 4 METS; and intense physical activity (running, cycling faster than 15 km/h, walking uphill fast or doing aerobics) equals 7 METS. 

Once identified, MET values should be multiplied by minutes per day and number of days a week the patient exercises (e.g. brisk walking for 40 minutes 4 days a week equals 640 MET minutes per week). A complete sedentary lifestyle equals 0 MET minutes/week.

This study included 131,558 individuals with cardiovascular disease and 310,240 individuals with no known cardiovascular disease followed for mean 5.9 years with all cause death as end point.


Read also: Exercise Programs in Peripheral Artery Disease.


There was an inverse correlation between physical activity and mortality in both populations. However, those with a history of cardiovascular disease (CVD) saw greater benefits from the same level of exercise than the ones with no history of CVD. For every 500 MET minutes per week of physical activity, there was a 14% reduction in mortality in patients with a history of CVD vs. 7% in patients with no history of CVD (p<0.001). In other words, the benefit of exercising is twice as high in the context of secondary prevention vs primary prevention. 

For patients with no history of CVD, one “dose” of exercise between 1 and 500 MET minutes per week seems enough, but individuals with CVD continue to benefit from 500 METS, even 1000 or more MET minutes per week. 

Adjusted mortality for CVD patients doing intense physical activity (>1000 MET minutes/week) is comparable and even lower than the group with no known CVD. This study tells us that CVD patient prognosis can be neutralized with regular exercise. Seeing as the cost/benefit ratio of exercising is still underestimated, it is without question essential to our consultation. 

2020-01-23-ehz564-abierto

Original Title: Mortality reduction with physical activity in patients with and without cardiovascular disease.

Reference: Sang-Woo Jeong et al. European Heart Journal (2019) 40, 3547–3555.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...